The evolution of hyperthermic intraperitoneal chemotherapy in the setting of advanced ovarian cancer
Ovarian cancer is the second most common, and first most lethal gynecological cancer. It will affect one in seventy-eight women, and is commonly diagnosed in the later stages of the disease. The majority of the cancer’s lifespan is spent within the peritoneal cavity. Hyperthermic intraperitoneal che...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en_US |
| Published: |
2019
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/2144/36605 |